

EVERYONE WANTS A SAFE AND EFFECTIVE COVID-19 VACCINE.



COVID-19 Vaccine Approval Process & Efforts to Ensure Equitable Distribution

Amy Pisani - Executive Director - Vaccinate Your Family Sarah Despres — Chair, Vaccinate Your Family Special Guest, Julie Tierney - Chief of Staff, CBER/FDA

Building Healthy Communities Vaccinate Your Family.org



















Personal Stories

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque vel augue lorem. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean dignissim purus sed arcu fermentum porttitor.



VYF Has Responses to Common Concerns https://www.vaccinateyourfamily.org/vaccine-safety/

Aren't vaccines just a way for pharmaceutical companies (Big Pharma) to make money?

If I'm breastfeeding my baby, why do I need to vaccinate him or her?

If some vaccines are grown in human fetal cells, is it against Christian religions to be vaccinated?



Who monitors the safety of vaccines in the United States?

How can I be confident that vaccines don't cause autism?

VYF Releases an Annual State of the ImmUnion Report

Insurance Coverage Should Not Dictate Access to Childhood Vaccinesxi



VACCINATION RATES FOR	PRIVATE INSURANCE	MEDICAID	UNINSURED
DTaP (24 doses):	87%	76%	60%
MMR (≥ 1 Dose):	94%	89%	73%
Flu (22 doses):	69%	48%	35%
Combined 7-Vaccine Series*:	75%	64%	47%
No vaccines:	0.8%	1.2%	7.4%

EVERYONE IN THE U.S. SHOULD

HAVE ACCESS TO VACCINES

Despite progress made since the establishment of the Vaccines For Children program in 1994, children still lack access to vaccines depending on where they live, their families' socioeconomic status, and their insurance status. Adults face similar challenges with additional racial and ethnic disparities.

2020: STATE OF THE IMMUNION | VACCINATE YOUR FAMILY | 11

DID YOU KNOW?



Adult vaccination rates for shingles, as seen in the following statistics from 2016, varied greatly among racial/ethnic groups.²¹

Whites

Blacks


Hispanics & Asians

38%

16%

22%

VYF developed the "State of the ImmUnion COVID Edition"



Program	Budget
Strengthen IIS Systems	\$400M
CDC Immunization Program	\$1B annual appropriation + \$900M one-time infusion
Influenza vaccination in 2020 and 2021	\$700M for flu vaccine purchase + \$300M for infrastructure grants

We Also Need to Begin to Solve Access Issues Now



Ensure **Medicare Part D** Programs cover vaccines at **no cost** to the patient



Ensure all children on CHIP are VFC-eligible




Ensure all **state Medicaid** programs cover vaccines at **no cost** to the patient



Identify underserved communities in your state and begin to develop outreach and distribution plans

Access our State of ImmUnion Reports @vaccinateyourfamily.org



As we await the vaccines... Efforts to Ensure Equitable Distribution



Charge to National Academies of Sciences, Engineering & Medicine ... Equitable Covid-19 Vaccine Distribution

"An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will develop an overarching framework for vaccine allocation to assist policymakers in the domestic and global health communities in planning for equitable allocation of vaccines against SARS-CoV-2. The expectation is that such a framework would inform the decisions by health authorities, including the Advisory Committee on Immunization Practices (ACIP), as they create and implement national and/or local guidelines for SARS-CoV-2 vaccine allocation."

NAM -Info related to the committee's work can be found on the project website here: https://www.nationalacademies.org/our-work/a-framework-for-equitable-allocation-of-vaccine-for-the-novel-coronavirus.

VYF comments on first draft are available here: https://www.vaccinateyourfamily.org/about-us/announcements/

- Selected published frameworks for early COVID-19 vaccine allocation
- World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE)
- Johns Hopkins Bloomberg School of Public Health
- The National Academies of Sciences, Engineering, and Medicine

Presented by Sarah Oliver, CDC/NCIRD to the ACIP Sept. 2020

COVID-19 vaccine priority group comparison

Group	Johns Hopkins	National Academies	WHO
Healthcare personnel	Tier 1: Frontline healthcare personnel including LTCF providers; EMS Tier 2: HCP & staff with direct, non-COVID patient contact; pharmacy workers	Phase 1a: Frontline healthcare personnel including LTCF providers; EMS Phase 2: Other healthcare personnel	Priority groups unranked
Other essential workers	Tier 1: Public transport, food supply workers; teachers & school workers. Workers necessary for pandemic support: (e.g. vaccine manufacturers; public health workers/support) Tier 2: Frontline infrastructure; warehouse/delivery/postal; deployed military; police & fire; TSA and border security; high-density or high-contact jobs	Phase 1a: Police, fire Phase 2: Critical infrastructure at risk of exposure; teachers and school staff incl childcare workers	
Underlying medical conditions	er 1: Those with elevated risk of serious disease; members social groups experiencing disproportionately high fatality tes Phase 1b: Significantly higher risk (≥2 CDC designated co		
Adults ≥65 years of age	Tier 1: Adults ≥65 years including those living with or providing care to them	Phase 1b: Older adults in congregate settings Phase 2: All older adults not in Phase 1	

17

Presented by Kathleen Dooling, CDC/NCIRD to the ACIP Sept. 2020

Possible groups for Phase 1 vaccination

August ACIP meeting

Phase 1a:


-HCP

Phase 1b:

- -Essential Workers
- -High Risk Med Conditions
- -Adults ≥ 65 years old


September ACIP meeting

- -Explore groups for phase 1b
- -risk for COVID-19
- -overlap between groups
- -racial and ethnic composition
- -Summary of Work Group considerations



Presented by Kathleen Dooling, CDC/NCIRD to the ACIP Sept. 2020

Overlap: Essential Worker & High-Risk Medical Conditions



New Safety System for Essential Workers - COVID

Presented by Tom Shimabukuro, CDC/NCIRD to the ACIP Sept. 2020

Vaccine safety assessment for essential workers (V-SAFE)



 Text messages or email from CDC with follow-up – daily 1st week post-vaccination and weekly thereafter out to 6 weeks



2. Any clinically important event(s) reported by vaccinated person

Healthcare workers, essential workers, etc.

VAERS call center



© Vaccinate Your Family, 2020

3. Follow-up on clinically important event, complete a VAERS report if appropriate





14



FDA's Role in COVID-19 Vaccine Development

Julia Tierney, JD

Chief of Staff

Food and Drug Administration

Center for Biologics Evaluation and Research





FDA's Role in COVID-19 Vaccine Development

Julia Tierney, JD

Chief of Staff

Food and Drug Administration

Center for Biologics Evaluation and Research